Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease
NCT07536490, Completed, Ankara University
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07536490 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 69 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Ankara University | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| First posted | 2026-04-17 | ClinicalTrials.gov |
| Last updated | 2026-06-16 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Sleep Quality | Baseline | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. | ClinicalTrials.gov |
| Primary | Stroop Test | Baseline | Cognitive flexibility and selective attention will be assessed using the Stroop Test. Completion time and error rates will be recorded, with longer times and higher error rates indicating poorer performance. Time Frame: Baseline | ClinicalTrials.gov |
| Primary | Clock Drawing Test | Baseline | Visuospatial ability and executive function will be assessed using the Clock Drawing Test. Scores will be recorded based on standard scoring criteria, with lower scores indicating impaired performance. | ClinicalTrials.gov |
| Primary | Disease Severity | Baseline | Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale. Higher scores indicate greater disease severity. | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment | Baseline | Global cognitive function will be assessed using the Montreal Cognitive Assessment. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment. | ClinicalTrials.gov |
| Secondary | Disease Stage | Baseline | Disease stage will be determined using the Modified Hoehn and Yahr Scale. Higher stages indicate more advanced disease. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Clock Drawing Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)